The efficacy of DPP-4 inhibitor after pancreatectomy

The efficacy of DPP-4 inhibitor after pancreatectomy - The efficacy of DPP-4 inhibitor after pancreatectomy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003722

Enrollment

Registered

2010-07-01

Start date

2010-07-01

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bebign diseases of pancreas 1)Serous cyst adenoma 2) Mucinous cyst adenoma 3) Lymphoepithelial cyst 4)Intraductal papillary mucinous neoplasm

Interventions

DPP-4 inhibitor

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: 1)The patients who have duodenal obstruction. 2)The patients who have anastomosis insufficiency and intraabdominal abscess after operation. 3)The patients who have no agreement. 4)Advanced cancer patients.

Design outcomes

Primary

Measure	Time frame
Comparison of pancreatic beta cell function and GLP-1 after DPP-4 inhibitor.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026